NCT07162883View on ClinicalTrials.gov

Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

122

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

May 31, 2027

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

QL2107

IV infusion.

DRUG

Keytruda®

IV infusion.

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY